Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma

NCT01273662 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT01273662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01273662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma
Lead sponsor
National Taiwan University Hospital
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2011
Completion date
December 31, 2016
Enrollment
45 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma